The FDA has stopped all pediatric clinical trials of Sensipar (cinacalcet hydrochloride) from Amgen, after the recent death of a...
The Phase III EVOLVE" (EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events) trial results were announced by Amgen, which...
Amgen has announced the Journal of the American Medical Association (JAMA) publication of findings from three Phase III studies of...
Amgen has announced results from the head-to-head Phase III study comparing AMG 416 with cinacalcet for the treatment of secondary...
Amgen announced that the FDA has issued a Complete Response Letter for the New Drug Application (NDA) for Parsabiv (etelcalcetide)...
Amgen announced the submission of a Marketing Authorisation Application to the European Medicines Agency via the centralised procedure for etelcalcetide...